XyloCor Therapeutics, Inc.
8910 University Center Lane
2 articles with XyloCor Therapeutics, Inc.
XyloCor Therapeutics Raises $17 Million in Series A Financing to Advance Gene Therapy Portfolio in Cardiovascular Disease
- Novel gene therapy for patients with treatment-resistant angina who have no remaining treatment options is ready to enter clinical development -
Grants rights to research, develop and commercialize antibodies generated using the AlivaMab Mouse platform